Abstract 465P
Background
This study evaluated the quality of oncological care of people with mental illness at an outer metropolitan centre.
Methods
A retrospective review of multidisciplinary team meetings (MDTs) was conducted and those with comorbid mental illness (“cases”) were identified. Demographic, psychiatric and oncological data were collected. Mental illness was stratified to 3 categories – Cat 1: mild affective disorders (uncomplicated depression/anxiety); Cat 2: complicated affective disorders (e.g. depression/anxiety with prior suicide attempt, hospitalisation and/or case management, substance use disorder and post-traumatic stress disorder); and Cat 3: severe mental illness (SMI) (e.g. bipolar affective disorder and schizophrenia). Patients without mental illness (“controls”) were randomly selected from the same tumour stream MDTs. Comparison between cases and controls was performed using Fisher’s exact test.
Results
Between 2021-2022, 853 patients were discussed at MDTs. 170 (20%) cases were identified, of whom 57%, 29% and 14% were in Cat 1, 2 and 3 respectively. Corresponding 170 controls were selected at random. Median age for cases was 65 vs. 71 for controls, p=0.03. No differences in sex and ethnicity were found. Cat 3 cases had the highest proportion receiving government financial aid (87%) vs. controls (57%) (Cat 1: 68%, Cat 2: 78%) p=0.001. Cat 3 cases also had the highest rates of ≥3 non-attendances to appointments (22%) vs. controls (7%) (Cat 1: 12%, Cat 2: 18%) p=0.006. Cases were found to have higher rates of metastatic disease at presentation (26% vs. 15% for controls, p=0.01). For patients offered active palliative treatment (n=80), cases had reduced adherence to the recommended treatment plan (70% vs. 91% for controls, p=0.03). Of those offered curative treatment (n=237), Cat 3 cases had the highest rates of cancer recurrence (33%) vs. controls (9%) (Cat 1: 12%, Cat 2: 18%) p=0.03.
Conclusions
Mental illness was associated with poorer cancer outcomes with increasing severity associated with even poorer outcomes, potentially reflecting higher rates of treatment non-adherence. This institutional study suggests that people with SMI have increased needs in navigating cancer care and highlights a need to examine this on a larger scale.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Z.W. Wong: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Other, Travel grant: Pfizer. Y. Antill: Financial Interests, Personal, Invited Speaker: GSK, MSD, AstraZeneca, Lilly, Eisai; Financial Interests, Institutional, Research Funding: AstraZeneca, MSD; Financial Interests, Personal, Advisory Board: GSK, MSD, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract